Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01677572 : Multiple Dose Study of BIIB037 (Recombinant, Fully Human Anti-A? IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
PhasePhase 1
AgesMin: 50 Years Max: 90 Years
Eligibility
Key Inclusion Criteria:

- Subjects must meet criteria for Prodromal Alzheimer's Disease (AD) or Mild
Alzheimer's Disease (AD):

1. Mini Mental State Examination (MMSE) score between 20-30,

2. Clinical Dementia Rating Scale (CDR) score of 0.5 or 1.0.

3. A free recall score of lesser or equal to 27 on the Free and Cued Selective
Reminding Test (FCSRT) for prodromal Alzheimer's Disease (AD).

- Subjects must have a positive florbetapir positron emission tomography (PET) amyloid
scan.

- Subjects must consent to apolipoprotein E (ApoE) genotyping.

- Apart from clinical diagnosis of Alzheimer's Disease (AD), subject must be in good
health.

- Must have a reliable informant or caregiver.

Key Exclusion Criteria:

- Any medical or neurological condition (other than Alzheimer's Disease) that might be
a contributing cause of the subject's cognitive impairment.

- Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of
consciousness in the past 1 year.

- Clinically significant psychiatric illness in past 6 months.

- Seizure in the past 3 years.

- Poorly controlled diabetes mellitus.

- History of unstable angina, myocardial infarction, chronic heart failure, or clinical
significant conduction abnormalities within 1 year prior to Screening.

- Indication of impaired renal or liver function.

- Have human immunodeficiency virus (HIV) infection.

- Have a significant systematic illness or infection in past 30 days.

- Brain MRI showing evidence of acute or sub-acute micro or macrohemorrhage, greater
than 4 microhemorrhages, cortical infarct or greater than one 1 lunar infarct.

- Any contraindications to brain MRI or positron emission tomography (PET) scans.

- Negative positron emission tomography (PET) scan with any amyloid-targeting ligand
within 48 weeks of Screening.

- Clinically significant 12-lead electrocardiogram (ECG) abnormalities.

- Alcohol or substance abuse in past 1 year.

- Taking blood thinners (except for aspirin at a prophylactic dose or less)

- Have changes in medications or doses of medication in past 4 weeks.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01677572      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740